A meta-analysis of oxygenated hypothermic machine perfusion in kidney transplantation finds the approach may lower adverse events. The potential benefit is particularly noted in donation-after-cardiac-death cases.
Waters Medical Systems receives FDA 510(k) clearance for its DCX organ cassette. The cassette is part of an end-to-end platform integrating the RM4 kidney perfusion system, the DCX cassette, and Pulsatile Preservation Solution.
Hypothermic machine perfusion enables delayed kidney transplantation after 83 hours of cold ischemia in a combined liver-kidney transplant. The technique extends the interval between organ procurement and transplant, limiting cold ischemia’s harmful effects and decreasing delayed graft function.
The study evaluates active oxygenation during hypothermic machine perfusion of kidney grafts from deceased-after-cardiac-death donors using a novel perfusion machine.
